Gastric Neuroendocrine Tumor Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Gastric Neuroendocrine Tumor. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Gastric Neuroendocrine Tumor receives a directional score of 64/100, combining unmet need (79/100), competitive intensity (75/100) and market attractiveness (76/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the stomach.

The reproducible record is Patsnap disease ID 1a553d622c384aa2af25fa323eec10f3. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: 中国及全球胃癌流行特征分析 Epidemiological characteristics of gastric cancer in China and worldwide

总体而言，全球胃癌的发病率和死亡率呈现下 降趋势，但在不同地区、性别及年龄组间存在明显 差异。东亚地区胃癌发病和死亡负担尤为沉重，与 日本和韩国相比，中国胃癌发病率低但标化死亡率 高，且中国胃癌发病率和死亡率明显高于其他高 HDI地区，反映了胃癌防控的巨大挑战。随着人口 老龄化的加剧，中国的胃癌防控形势将更加严峻。 未来需要进一步加强胃癌防控措施，减少危险因素 暴露，扩大筛查覆盖面，推广规范化诊疗，以改善我 国胃癌流行现状，持续降低发病率和死亡率，减轻 我国胃癌的疾病负担。 利益冲突 所有作者声明无利益冲突 作者贡献声明 余炜燕：论文撰写、数据整理、统计学分析；李雪、 朱娟：论文修改；丁雨蒙、陶欢青：数据核查；杜灵彬：研究指导、论 文修改、经费支持 参 考 文 献

Review source

Epidemiology evidence 2: The Burden and Risk Factors of Gastric Cancer in Eastern Asia From 1990 to 2021: Longitudinal Observational Study of the Global Burden of Disease Study 2021 The Burden and Risk Factors of Gastric Cancer in EasternAsia From 1990 to 2021: Longitudinal Observational Study ofthe Global Burden of Disease Study 2021

The Burden and Risk Factors of Gastric Cancer in Eastern Asia From 1990 to 2021: Longitudinal Observational Study of the Global Burden of Disease Study 2021 The Burden and Risk Factors of Gastric Cancer in Eastern Asia From 1990 to 2021: Longitudinal Observational Study of the Global Burden of Disease Study 2021 Weijia Kong1,2*, PhD; Yuting Sun1*, PhD; Xiaoyan Qin1,2*, PhD; Guanghui Zhu1, PhD; Xiaoyu Zhu1, PhD; Ziyu Kuang1,2, PhD; Zhigang Xiao1, PhD; Jie Li1, MD 1Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China 2Graduate School, Beijing University of Chinese Medicine, Beijing, China *these authors contributed equally Corresponding Author: Jie Li, MD Guang’anmen Hospital, China Academy of Chinese Medical Sciences 5 Beixiange Street, Xicheng District Beijing 10053 China Phone: +86-10-83123311 Email: qfm2020jieli@yeah.net Abstract Background: Eastern Asia has historically had the highest global incidence and mortality rates of gastric cancer (GC) while substantial disparities exist between countries. The overall burden of GC remains insufficiently explored. Objective: Using the Global Burden of Disease Study 2021, this research aims to estimate the burden and risk factors of GC in Eastern Asia from 1990 to 2021. Methods: Incidence, age-standardized incidence rate (ASIR), deaths, age-standardized mortality rate (ASMR), disability- adjusted life years, age-standardized disability-adjusted life year rate (ASDR), and risk factor burdens for GC were analyzed in Eastern Asia from 1990 to 2021. Joinpoint analysis determined average annual percent change

Review source

Epidemiology evidence 3: Global Cancer Statistics, 2002

There has been a steady decline in the risk of gastric cancer incidence and mortality over several decades in most countries.43 The worldwide estimates of age adjusted inci- dence (22.0 per 100,000 in men and 10.3 per 100,000 in women) are about 15% lower than the values estimated in 1985.17 This decline may be related to improvements in preservation and storage of foods; it may also represent changes in the prevalence of H. pylori by birth cohort, perhaps as a result of reduced transmission in childhood, following a trend to improved hygiene and reduction of crowding.44,45 If the observed secular de- cline continues, the expected number of new cases in 2010 will be around 1.1 million (an increase of 19%), rather than the 21% addi- tional cases due simply to a population growth and aging. Prostate Cancer

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Gastric Neuroendocrine Tumor, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Gastric Neuroendocrine Tumor thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor is PTH1R, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 53 registered studies.

• NCT07728292 — Safety and Efficacy of Underwater Endoscopic Mucosal Resection for Type I Gastric Neuroendocrine Tumors Measuring 5-9 mm (POEM); Recruiting; Not Applicable; sponsor Asian Institute of Gastroenterology Pvt Ltd.; enrollment 60.
• NCT07653126 — A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany (LUNET-2); Completed; Not Applicable; sponsor Novartis Pharmaceuticals Canada, Inc.; enrollment 117.
• NCT07640737 — AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study) (BHARAT-3); Not yet recruiting; Phase 2; sponsor Aurigene Oncology Ltd.; enrollment 30.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate PTH1R relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Gastric Neuroendocrine Tumor merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Gastric Neuroendocrine Tumor is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.